Profusa, Inc. (PFSA)
NASDAQ: PFSA · Real-Time Price · USD
2.450
-0.430 (-14.93%)
Sep 9, 2026, 3:36 PM EDT - Market open
Profusa Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
1.48M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 100.00K | 55.00K | 122.22% |
| Dec 31, 2023 | 45.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 742.00K | -3.20M | -81.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vivos Therapeutics | 20.90M |
| Nuwellis | 9.01M |
| Beyond Air | 7.69M |
| INVO Fertility | 7.53M |
| Tenon Medical | 5.31M |
| ENvue Medical | 1.93M |
| Catheter Precision | 1.92M |
| Nexalin Technology | 217.16K |
PFSA News
- 9 days ago - Profusa regains compliance with Nasdaq - TheFly
- 9 days ago - Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement - GlobeNewsWire
- 16 days ago - Profusa Inc trading resumes - TheFly
- 16 days ago - Profusa Inc trading halted, volatility trading pause - TheFly
- 20 days ago - Profusa Inc trading resumes - TheFly
- 20 days ago - Profusa Inc trading halted, volatility trading pause - TheFly
- 20 days ago - Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company - GlobeNewsWire
- 23 days ago - Profusa announces 1-for-4 reverse stock split - TheFly